W16-P-031 Fluvastatin safety profile in patients with low levels of ldl cholesterol in the Lescol® intervention prevention study

Pedro A. Lemos; Chourmouzios A. Arampatzis; Dick Goedhart; Claudio Gimpelewicz; M. Freudenreich; J.O. Logani; M. Bortolini; Patrick W. Serruys

doi:10.1016/s1567-5688(05)80427-1

W16-P-031 Fluvastatin safety profile in patients with low levels of ldl cholesterol in the Lescol® intervention prevention study

Atherosclerosis Supplements 6(1): 108-108

Article 2005 English

Related publications

Article2003

Fluvastatin prevents cardiac events following successful percutaneous coronary intervention in patients with multivessel disease: The lescolfi intervention prevention study

Pedro A. Lemos, G. Boxho, Dick Goedhart, Brian J. O’Neil, J. P. Broustet, Gunnar H. Berghoefer, C. Alonso, A. Boehmer, Pim de Feyter, Patrick W. Serruys

Journal of the American College of Cardiology

Article2006

Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention

Patrick W. Serruys, Pim de Feyter, Carlos Macaya, N. Kokott, Jean‐Luc Puel, Matthias Vrolix, Angelo Branzi, Marcelo Chiara Bertolami, Graham Jackson, Bradley H. Strauss, Bernhard Meier

Article2005

Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention—A Lescol Intervention Prevention Study (LIPS) substudy

Chourmouzios A. Arampatzis, Dick Goedhart, Patrick W. Serruys, Francesco Saia, Pedro A. Lemos, Pim de Feyter

American Heart Journal

Article1997

2.P.9 Reduced plasma HDL-cholesterol levels in visceral obesity: Contribution of the CETP gene TaqIB polymorphism

Marie‐Claude Vohl, Benoı̂t Lamarche, Gaël Le Roux, Denis Prud’homme, Claude Bouchard, A Nadeau, J. Després

Atherosclerosis

Article2004

Fluvastatin Reduces Cardiac Mortality in Patients with Coronary Heart Disease

Christie M. Ballantyne, Günter A.J. Riegger, Nicholas Moore, Francesco Saia, Patrick W. Serruys

Cardiovascular Drugs and Therapy

W16-P-031 Fluvastatin safety profile in patients with low levels of ldl cholesterol in the Lescol® intervention prevention study

Abstract

Discussion(0)

Related publications

Fluvastatin prevents cardiac events following successful percutaneous coronary intervention in patients with multivessel disease: The lescolfi intervention prevention study

Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention

Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention—A Lescol Intervention Prevention Study (LIPS) substudy

2.P.9 Reduced plasma HDL-cholesterol levels in visceral obesity: Contribution of the CETP gene TaqIB polymorphism

Fluvastatin Reduces Cardiac Mortality in Patients with Coronary Heart Disease